CAR-T Cell Therapy MarketCAR-T Cell Therapy Market 18.5 CAGR Growth Outlook 2024-2030
CAR-T Cell Therapy Market by Drug Type (Axicabtagene Ciloleucel (Yescarta), by Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), by End-user (Hospitals, Oncology Treatment Centers), by North America (U.S., Canada) Forecast 2024-2032
Base Year: 2023
150 Pages
CAR-T Cell Therapy Market 18.5 CAGR Growth Outlook 2024-2030
Key Insights
The CAR-T Cell Therapy Market size was valued at USD 2.72 USD billion in 2023 and is projected to reach USD 8.92 USD billion by 2032, exhibiting a CAGR of 18.5 % during the forecast period. Immunotherapy using CAR-T cells is one of the revolutionary treatments that strengthen the body’s response against cancer cells. It includes the manipulation of T cells extracted from a patient and afterward causing the T cells to exhibit chimeric antigen receptors (CARs) that are exact to cancerous tissue antigens therefore permitting the T cells to identify and destroy cancers. There are two primary types: where the cells used are the patient’s cells, and allogeneic where cells from a donor are used. This therapy has excellent specificity as CAR-T cells recognize cancer cells and not healthy tissues. The current research saw its use in different types of cancer especially leukemia and lymphoma with positive outcomes even in the late stages of cancer when other means of treatments do not work.
CAR-T Cell Therapy Trends
- Increasing prevalence of cancer worldwide
- Rising demand for personalized and targeted cancer therapies
- Government initiatives and funding for cancer research
Driving Forces: What's Propelling the CAR-T Cell Therapy Market
- Advancements in gene editing and engineering technologies
- Growing adoption of CAR-T cell therapy in clinical trials
- Need for improved treatment outcomes in cancer patients
Challenges and Restraints in CAR-T Cell Therapy Market
- High cost of CAR-T cell therapy, including manufacturing and administration
- Safety concerns related to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)
- Limited number of approved CAR-T cell therapies targeting specific indications
- Difficulty in manufacturing CAR-T cells at a large scale to meet market demand
- Intellectual property disputes and patent litigation involving CAR-T cell technologies
Emerging Trends in CAR-T Cell Therapy
- Development of next-generation CAR-T cells with enhanced efficacy and safety
- Integration of artificial intelligence and machine learning in CAR-T cell engineering
- Combination of CAR-T cell therapy with other cancer treatments
Growth Catalysts in CAR-T Cell Therapy Industry
- Increasing research and development funding from pharmaceutical companies and government agencies
- Growing collaborations between industry and academia to advance CAR-T cell therapies
- Government support and incentives for the development and commercialization of CAR-T therapies
- Expanding clinical trials and regulatory approvals for new CAR-T cell products
- Advances in gene editing technologies, such as CRISPR-Cas9, enabling more precise modifications and enhancements to CAR-T cells
Market Segmentation: CAR-T Cell Therapy Analysis
Drug Type
- Axicabtagene Ciloleucel (Yescarta)
- Tisagenlecleucel (Kymriah)
- Brexucabtagene Autoleucel (Tecartus)
- Lisocabtagene Maraleucel (Breyanzi)
End-user
- Hospitals
- Oncology Treatment Centers
Leading Players in the CAR-T Cell Therapy Market
- Gilead Sciences, Inc. (U.S.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Johnson & Johnson Services, Inc. (Janssen Global Services, LLC) (U.S.)
- Caribou Biosciences, Inc. (U.S.)
Significant Developments in the CAR-T Cell Therapy Sector
- Approval of new CAR-T cell therapies for the treatment of various cancers
- Expansion of clinical trials and research programs
- Strategic collaborations and acquisitions between market players
Comprehensive Coverage CAR-T Cell Therapy Market Report
The report provides an in-depth analysis of the CAR-T cell therapy market, covering the following aspects:
- Market Dynamics
- Industry Analysis
- Competitive Landscape
- Market Forecast
- Product Landscape
Pricing Analysis
- Price Trends
- Price Comparisons
- Price Segmentation
Import And Export Analysis
- Import Regulations
- Export Regulations
- Import-Export Data
Segmentation
- By Type
- By Application
- By End-user
Patent/Trademark Analysis
- Patent Filings
- Trademark Registrations
- Patent and Trademark Landscape
CAR-T Cell Therapy Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 18.5% from 2018-2032 |
| Segmentation |
|
Frequently Asked Questions
Table Of Content
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Prevalence of Hematological Cancer to Surge the Demand for CAR-T Cell Therapy
- 3.3. Market Restrains
- 3.3.1. High Treatment Cost of the Expensive Drugs is Limiting the Adoption of the Therapy
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2018-2030
- 5.1. Market Analysis, Insights and Forecast - by Drug Type
- 5.1.1. Axicabtagene Ciloleucel (Yescarta
- 5.2. Market Analysis, Insights and Forecast - by Indication
- 5.2.1. Acute Lymphoblastic Leukemia
- 5.2.2. Non-Hodgkin Lymphoma
- 5.2.3. Multiple Myeloma
- 5.3. Market Analysis, Insights and Forecast - by End-user
- 5.3.1. Hospitals
- 5.3.2. Oncology Treatment Centers
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.1. Market Analysis, Insights and Forecast - by Drug Type
- 6. Northeast CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2018-2030
- 6.1. Market Analysis, Insights and Forecast - By Drug Type
- 6.1.1. Axicabtagene Ciloleucel (Yescarta)
- 6.2. Market Analysis, Insights and Forecast - By Indication
- 6.2.1 Acute Lymphoblastic Leukemia
- 6.2.2 Non-Hodgkin Lymphoma
- 6.2.3 and Multiple Myeloma
- 6.3. Market Analysis, Insights and Forecast - By End-user
- 6.3.1 Hospitals
- 6.3.2 Oncology Treatment Centers
- 7. Southeast CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2018-2030
- 7.1. Market Analysis, Insights and Forecast - By Drug Type
- 7.1.1. Axicabtagene Ciloleucel (Yescarta)
- 7.2. Market Analysis, Insights and Forecast - By Indication
- 7.2.1 Acute Lymphoblastic Leukemia
- 7.2.2 Non-Hodgkin Lymphoma
- 7.2.3 and Multiple Myeloma
- 7.3. Market Analysis, Insights and Forecast - By End-user
- 7.3.1 Hospitals
- 7.3.2 Oncology Treatment Centers
- 8. Midwest CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2018-2030
- 8.1. Market Analysis, Insights and Forecast - By Drug Type
- 8.1.1. Axicabtagene Ciloleucel (Yescarta)
- 8.2. Market Analysis, Insights and Forecast - By Indication
- 8.2.1 Acute Lymphoblastic Leukemia
- 8.2.2 Non-Hodgkin Lymphoma
- 8.2.3 and Multiple Myeloma
- 8.3. Market Analysis, Insights and Forecast - By End-user
- 8.3.1 Hospitals
- 8.3.2 Oncology Treatment Centers
- 9. Southwest CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2018-2030
- 9.1. Market Analysis, Insights and Forecast - By Drug Type
- 9.1.1. Axicabtagene Ciloleucel (Yescarta)
- 9.2. Market Analysis, Insights and Forecast - By Indication
- 9.2.1 Acute Lymphoblastic Leukemia
- 9.2.2 Non-Hodgkin Lymphoma
- 9.2.3 and Multiple Myeloma
- 9.3. Market Analysis, Insights and Forecast - By End-user
- 9.3.1 Hospitals
- 9.3.2 Oncology Treatment Centers
- 10. West CAR-T Cell Therapy Market Analysis, Insights and Forecast, 2018-2030
- 10.1. Market Analysis, Insights and Forecast - By Drug Type
- 10.1.1. Axicabtagene Ciloleucel (Yescarta)
- 10.2. Market Analysis, Insights and Forecast - By Indication
- 10.2.1 Acute Lymphoblastic Leukemia
- 10.2.2 Non-Hodgkin Lymphoma
- 10.2.3 and Multiple Myeloma
- 10.3. Market Analysis, Insights and Forecast - By End-user
- 10.3.1 Hospitals
- 10.3.2 Oncology Treatment Centers
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2023
- 11.2. Company Profiles
- 11.2.1 Gilead Sciences Inc. (U.S.)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Novartis AG (Switzerland)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Bristol-Myers Squibb Company (U.S.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Johnson & Johnson Services Inc. (Janssen Global Services
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 LLC) (U.S.)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Caribou Biosciences Inc. (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 CARsgenTherapeutics Co. Ltd (China)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 JW Therapeutics (Shanghai) Co. Ltd. (China)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Cartesian Therapeutics Inc. (U.S.)
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Aurora Biopharma (U.S.)
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.1 Gilead Sciences Inc. (U.S.)
List of Figures
- Figure 1: Global CAR-T Cell Therapy Market Revenue Breakdown (USD billion, %) by Region 2023 & 2031
- Figure 2: Global CAR-T Cell Therapy Market Revenue (USD billion), by Drug Type 2023 & 2031
- Figure 3: Global CAR-T Cell Therapy Market Revenue Share (%), by Drug Type 2023 & 2031
- Figure 4: Global CAR-T Cell Therapy Market Forecast (USD billion), by Axicabtagene Ciloleucel (Yescarta 2020 & 2031
- Figure 5: Global CAR-T Cell Therapy Market Revenue (USD billion), by Indication 2023 & 2031
- Figure 6: Global CAR-T Cell Therapy Market Revenue Share (%), by Indication 2023 & 2031
- Figure 7: Global CAR-T Cell Therapy Market Forecast (USD billion), by Acute Lymphoblastic Leukemia 2020 & 2031
- Figure 8: Global CAR-T Cell Therapy Market Forecast (USD billion), by Non-Hodgkin Lymphoma 2020 & 2031
- Figure 9: Global CAR-T Cell Therapy Market Forecast (USD billion), by Multiple Myeloma 2020 & 2031
- Figure 10: Global CAR-T Cell Therapy Market Revenue (USD billion), by End-user 2023 & 2031
- Figure 11: Global CAR-T Cell Therapy Market Revenue Share (%), by End-user 2023 & 2031
- Figure 12: Global CAR-T Cell Therapy Market Forecast (USD billion), by Hospitals 2020 & 2031
- Figure 13: Global CAR-T Cell Therapy Market Forecast (USD billion), by Oncology Treatment Centers 2020 & 2031
- Figure 14: Global CAR-T Cell Therapy Market Revenue (USD billion), by Region 2023 & 2031
- Figure 15: Global CAR-T Cell Therapy Market Revenue Share (%), by Region 2023 & 2031
- Figure 16: United states CAR-T Cell Therapy Market Revenue (USD billion), by Drug Type 2023 & 2031
- Figure 17: United states CAR-T Cell Therapy Market Revenue Share (%), by Drug Type 2023 & 2031
- Figure 18: United states CAR-T Cell Therapy Market Revenue (USD billion), by Indication 2023 & 2031
- Figure 19: United states CAR-T Cell Therapy Market Revenue Share (%), by Indication 2023 & 2031
- Figure 20: United states CAR-T Cell Therapy Market Revenue (USD billion), by End-user 2023 & 2031
- Figure 21: United states CAR-T Cell Therapy Market Revenue Share (%), by End-user 2023 & 2031
- Figure 22: United states CAR-T Cell Therapy Market Revenue (USD billion), by Country 2023 & 2031
- Figure 23: United states CAR-T Cell Therapy Market Revenue Share (%), by Country 2023 & 2031
- Figure 24: North America CAR-T Cell Therapy Market Revenue (USD billion), by Drug Type 2023 & 2031
- Figure 25: North America CAR-T Cell Therapy Market Revenue Share (%), by Drug Type 2023 & 2031
- Figure 26: North America CAR-T Cell Therapy Market Revenue (USD billion), by Indication 2023 & 2031
- Figure 27: North America CAR-T Cell Therapy Market Revenue Share (%), by Indication 2023 & 2031
- Figure 28: North America CAR-T Cell Therapy Market Revenue (USD billion), by End-user 2023 & 2031
- Figure 29: North America CAR-T Cell Therapy Market Revenue Share (%), by End-user 2023 & 2031
- Figure 30: North America CAR-T Cell Therapy Market Revenue (USD billion), by Country 2023 & 2031
- Figure 31: North America CAR-T Cell Therapy Market Revenue Share (%), by Country 2023 & 2031
List of Tables
- Table 1: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Drug Type 2018 & 2031
- Table 2: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Indication 2018 & 2031
- Table 3: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by End-user 2018 & 2031
- Table 4: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Region 2018 & 2031
- Table 5: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Drug Type 2018 & 2031
- Table 6: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Indication 2018 & 2031
- Table 7: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by End-user 2018 & 2031
- Table 8: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Region 2018 & 2031
- Table 9: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Drug Type 2018 & 2031
- Table 10: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Indication 2018 & 2031
- Table 11: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by End-user 2018 & 2031
- Table 12: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Country 2018 & 2031
- Table 13: Northeast CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
- Table 14: Southeast CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
- Table 15: Midwest CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
- Table 16: Southwest CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
- Table 17: West CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
- Table 18: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Drug Type 2018 & 2031
- Table 19: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Indication 2018 & 2031
- Table 20: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by End-user 2018 & 2031
- Table 21: Global CAR-T Cell Therapy Market Revenue USD billion Forecast, by Country 2018 & 2031
- Table 22: U.S. CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
- Table 23: Canada CAR-T Cell Therapy Market Revenue (USD billion) Forecast, by Application 2018 & 2031
| Aspects | Details |
|---|---|
| Study Period | 2018-2032 |
| Base Year | 2023 |
| Estimated Year | 2024 |
| Forecast Period | 2024-2032 |
| Historical Period | 2018-2023 |
| Growth Rate | CAGR of 18.5% from 2018-2032 |
| Segmentation |
|
STEP 1 - Identification of Relevant Samples Size from Population Database
STEP 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segemnts, product and application.
Note* : In applicable scenarios
STEP 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
STEP 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally after gathering mix and scattered data from wide range of sources, data is triangull- ated and correlated to come up with estimated figures which are further validated through primary mediums, or industry experts, opinion leader.
About Market Research Forecast
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
